Long non-coding RNA Zinc finger E-box binding homeobox 2 (ZEB2) antisense RNA 1 (ZEB2-AS1) has been shown to promote tumor progression. However, the clinical significance and fundamental function role of ZEB2-AS1 in osteosarcoma (OS) has been poorly understood.
Methods:
The expression of ZEB2-AS1 was determined in tumor tissues and matched normal tissues from 67 OS patients using quantitative reverse transcriptase PCR analysis. Clinical value of ZEB2-AS1 was evaluated by χ2 test and Kaplan-Meier method. Cell proliferation was analyzed using CCK-8 assay, colony formation. Cell apoptosis status was determined by caspase-3 activity assay. Cell migration, invasion and epithelial-mesenchymal transition (EMT) were investigated by scratch wound healing, transwell invasion assays and Western blotting.
Results:
Clinical association analysis revealed that high ZEB2-AS1 expression correlated with tumor size, distant metastasis and poor prognosis of OS patients. Moreover, ZEB2-AS1 expression was identified as an independent prognostic factor for OS patients. Loss-of-function assays demonstrated that ZEB2-AS1 knockdown suppressed the proliferation and induced apoptosis in OS cells. In addition, ZEB2-AS1 knockdown inhibited cell migration, invasion, EMT of OS cells in vitro.
Conclusions:
Taken together, our data demonstrate that ZEB2-AS1 serves a putative oncogenic role and associates with unfavorable prognosis in OS.
Get full access to this article
View all access options for this article.
References
1.
FergusonJL, TurnerSP. Bone Cancer: Diagnosis and treatment principles. Am Fam Phys, 2018; 98:205.
2.
TaranSJ, TaranR, MalipatilNB. Pediatric osteosarcoma: An updated review. Indian J Med Paediatr Oncol, 2017; 38:33.
3.
QiX, YuXJ, WangXM, et al.Knockdown of KCNQ1OT1 suppresses cell invasion and sensitizes osteosarcoma cells to CDDP by upregulating DNMT1-mediated Kcnq1 expression. Mol Ther Nucleic Acids, 2019; 17:804.
4.
BacciG, LonghiA, VersariM, et al.Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer, 2006; 106:1154.
5.
ReedDR, HayashiM, WagnerL, et al.Treatment pathway of bone sarcoma in children, adolescents, and young adults. Cancer, 2017; 123:2206.
6.
PengZQ, LuRB, XiaoDM, et al.Increased expression of the lncRNA BANCR and its prognostic significance in human osteosarcoma. Genet Mol Res, 2016; 15:30.
7.
FangY, FullwoodMJ. Roles, functions, and mechanisms of long non-coding RNAs in cancer. Genomics Proteomics Bioinformatics, 2016; 14:42.
8.
LiS. Expression of Concern: The functional role of long non-coding RNAs and epigenetics. Biol Proced Online, 2016; 18:12.
9.
SanchezY, HuarteM. Long non-coding RNAs: Challenges for diagnosis and therapies. Nucleic Acid Ther, 2013; 23:15.
10.
SunM, NieF, WangY, et al.LncRNA HOXA11-AS Promotes proliferation and invasion of gastric cancer by scaffolding the chromatin modification factors PRC2, LSD1, and DNMT1. Cancer Res, 2016; 76:6299.
11.
LiJ, ChenZ, TianL, et al.LncRNA profile study reveals a three-lncRNA signature associated with the survival of patients with oesophageal squamous cell carcinoma. Gut, 2014; 63:1700.
12.
LanT, ChangL, WuL, et al.Downregulation of ZEB2-AS1 decreased tumor growth and metastasis in hepatocellular carcinoma. Mol Med Rep, 2016; 14:4606.
13.
WangF, ZhuW, YangR, et al.LncRNA ZEB2-AS1 contributes to the tumorigenesis of gastric cancer via activating the Wnt/β-catenin pathway. Mol Cell Biochem, 2019; 456:73.
14.
WuF, GaoH, LiuK, et al.The lncRNA ZEB2-AS1 is upregulated in gastric cancer and affects cell proliferation and invasion via miR-143-5p/HIF-1alpha axis. Onco Targets Ther, 2019; 12:657.
15.
XuC, CuiH, LiH, et al.Long non-coding RNA ZEB2-AS1 expression is associated with disease progression and predicts outcome in gastric cancer patients. J BUON, 2019; 24:663.
16.
ShiX, LiJ, MaL, et al.Overexpression of ZEB2-AS1 lncRNA is associated with poor clinical outcomes in acute myeloid leukemia. Oncol Lett, 2019; 17:4935.
17.
MaH, SuR, FengH, et al.Long noncoding RNA UCA1 promotes osteosarcoma metastasis through CREB1-mediated epithelial-mesenchymal transition and activating PI3K/AKT/mTOR pathway. J Bone Oncol, 2019; 16:100228.
18.
ZhangGD, GaiPZ, LiaoGY, et al.LncRNA SNHG7 participates in osteosarcoma progression by down-regulating p53 via binding to DNMT1. Eur Rev Med Pharmacol Sci, 2019; 23:3602.
19.
GuoW, JiangH, LiH, et al.LncRNA-SRA1 suppresses osteosarcoma cell proliferation while promoting cell apoptosis. Technol Cancer Res Treat, 2019; 18:1533033819841438.
20.
ZhangGD, LiY, LiaoGJ, et al.LncRNA NKILA inhibits invasion and migration of osteosarcoma cells via NF-kappaB/Snail signaling pathway. Eur Rev Med Pharmacol Sci, 2019; 23:4118.
21.
IsakoffMS, BielackSS, PaulM, et al.Osteosarcoma: Current treatment and a collaborative pathway to success. J Clin Oncol, 2015; 33:JCO.2014.2059.4895.
22.
HarrisonDJ, GellerDS, GillJD, et al.Current and future therapeutic approaches for osteosarcoma. Expert Rev Anticancer Ther, 2018; 18:39.
23.
ChenD, WangH, ZhangM, et al.Abnormally expressed long non-coding RNAs in prognosis of Osteosarcoma: A systematic review and meta-analysis. J Bone Oncol, 2018; 13:76.
24.
DiaoP, GeH, SongY, et al.Overexpression of ZEB2-AS1 promotes epithelial-to-mesenchymal transition and metastasis by stabilizing ZEB2 mRNA in head neck squamous cell carcinoma. J Cell Mol Med, 2019; 23:4269.
SongN, LiuH, MaX, et al.Placental growth factor promotes ovarian cancer cell invasion via ZEB2. Cell Physiol Biochem, 2016; 38:351.
27.
YiX, ShiS, LiX, et al.[Expression and clinical significance of ZEB2 and E-cadherin in nasopharyngeal carcinoma]. J Clin Otorhinolaryngol Head Neck Surg, 2015; 29:1648.
28.
LiJ, YuanJ, YuanX, et al.MicroRNA-200b inhibits the growth and metastasis of glioma cells via targeting ZEB2. Int J Oncol, 2016; 48:541.
29.
PangX, HuangK, ZhangQ, et al.miR-154 targeting ZEB2 in hepatocellular carcinoma functions as a potential tumor suppressor. Oncol Rep, 2015; 34:3272.
30.
DeneckerG, VandammeN, AkayO, et al.Identification of a ZEB2-MITF-ZEB1 transcriptional network that controls melanogenesis and melanoma progression. Cell Death Differ, 2014; 21:1250.
31.
WangLJ, WuZH, ZhengXT, et al.Zinc Finger E-box binding protein 2 (ZEB2) suppress apoptosis of vascular endothelial cells induced by high glucose through mitogen-activated protein kinases (MAPK) pathway activation. Med Sci Monit Int Med J Exp Clini Res, 2017; 23:2590.
32.
WuX, YanT, WangZ, et al.LncRNA ZEB2-AS1 promotes bladder cancer cell proliferation and inhibits apoptosis by regulating miR-27b. Biomed Pharmacother, 2017; 96:299.
33.
LiuA, LiuL. Long non-coding RNA ZEB2-AS1 promotes proliferation and inhibits apoptosis of colon cancer cells via miR-143/bcl-2 axis. Am J Transl Res, 2019; 11:5240.
34.
De CraeneB, BerxG. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer, 2013; 13:97.
35.
HayED. An overview of epithelio-mesenchymal transformation. Acta Anat (Basel), 1995; 154:8.
36.
ThieryJP, AcloqueH, HuangRY, et al.Epithelial-mesenchymal transitions in development and disease. Cell, 2009; 139:871.
37.
BeltranM, PuigI, PenaC, et al.A natural antisense transcript regulates Zeb2/Sip1 gene expression during Snail1-induced epithelial-mesenchymal transition. Genes Dev, 2008; 22:756.
38.
ZhangG, LiH, SunR, et al.Long non-coding RNA ZEB2-AS1 promotes the proliferation, metastasis and epithelial mesenchymal transition in triple-negative breast cancer by epigenetically activating ZEB2. J Cell Mol Med, 2019; 23:3271.
39.
MillerBJ, CramP, LynchCF, BuckwalterJA. Risk factors for metastatic disease at presentation with osteosarcoma: an analysis of the SEER database. J Bone Joint Surg Am, 2013; 95:e89.
40.
WuQ, ZhouW, FengQ, LiuX, XiongY, LiH. MicroRNA-92b promotes cell proliferation and invasion in osteosarcoma by directly targeting Dickkopf-related protein 3. Exp Ther Med Jan, 2018; 15:173.
